# This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R

> **NCT07412405** · NA · NOT_YET_RECRUITING · sponsor: **GUSTAVO SALGUERO** · enrollment: 12 (estimated)

## Conditions studied

- Adult B-cell Acute Lymphoblastic Leukemia
- Follicular Lymphoma (FL)
- Mantle Cell Lymphoma (MCL)
- Diffuse Large B-Cell Lymphoma (DLBCL)
- Chronic Lymphocytic Leukemia

## Interventions

- **BIOLOGICAL:** ARI-0001 T cells with anti-CD19 chimeric antigen receptor (CAR-T)

## Key facts

- **NCT ID:** NCT07412405
- **Lead sponsor:** GUSTAVO SALGUERO
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2028-09-01
- **Final completion:** 2029-09-01
- **Target enrollment:** 12 (ESTIMATED)
- **Last updated:** 2026-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07412405

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07412405, "This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including R". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07412405. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*